<DOC>
	<DOCNO>NCT01350856</DOCNO>
	<brief_summary>Because artemisinins potent antimalarial drug , reduction parasite number rapid . Therefore , early measure reduce parasite count need . This study look conventional marker parasite reduction e.g . parasite clearance time , parasite reduction ratio , time achieve fall 50 % , 90 % 99 % pre-treatment parasitaemia . Defining artemisinin resistance require use artesunate ( AS ) alone appreciated partner drug combination treatment significant impact rate parasite clearance . This study dose patient 3 day AS alone ( long parasite clear ) measure parasite count frequently order able define accurate regression line graph natural logarithm parasite count ( Y axis ) versus time ( X axis ) . This follow full course artemisinin combination therapy ( ACT ) . Two different dose regimen artesunate compare site except western Cambodia , unpublished observation Thai-Myanmar border suggest standard low daily dose 2mg/kg may enable early detection low level resistance 4mg/kg daily dose .</brief_summary>
	<brief_title>Tracking Resistance Artemisinin ( TRAC )</brief_title>
	<detailed_description>Background : Artemisinins cornerstone current antimalarial treatment . Evidence reduce susceptibility artemisinins Western Cambodia first present January 2007 confirm subsequent detail pharmacokinetic-pharmacodynamic study conduct group . Artemisinin resistance manifest mark slow parasite clearance . The spread highly artemisinin resistant falciparum malaria would devastate consequence malaria control elimination . The response artemisinin resistance P. falciparum depend critically upon answer one pivotal question : far spread ? This research proposal focus fill critical gap knowledge essential plan effective response . Objectives/Hypothesis/Questions : This multi-centre study primary objective comparing P. falciparum parasite clearance compare reference parasite clearance rate obtain historical data artemisinin sensitive falciparum malaria . The aim large scale study determine artemisinin resistance spread , far spread . Research design : This multi-centre , open-label randomised trial assess clearance rate peripheral blood P. falciparum parasitaemia patient acute uncomplicated falciparum malaria treat two different dos artesunate . The study recruit patient acute uncomplicated P. falciparum malaria . The total number patient study expected 1800 . Patients randomise 1:1 receive either : - AS2 : Artesunate 2 mg/kg/day 3 day OR - AS4 : Artesunate 4 mg/kg/day 3 day - follow full course Artesunate- mefloquine ( MAS3 ) Patients hospitalise least 1st three day . During hospitalisation , patient malaria parasite count do 0 , 4 , 6 , 8 , 12 , every 6 hour parasite clearance . The weekly follow day 14 ( Day 7 Day 14 ) . Value significance research The study aim address simple crucial question regard artemisinin resistance currently answer : artemisinin resistant Plasmodium falciparum spread Western Cambodia ? The result determine approach subsequent effort ; strengthen strategy eliminate resistant parasite Western Cambodia resistance confine area , containment malaria control resistant parasite already spread . Potential outcome Within one year expect produce map geographical extent , prevalence severity artemisinin resistance .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Piperaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Mefloquine</mesh_term>
	<criteria>Male female , age 6 month 65 year old , inclusive Acute uncomplicated P. falciparum malaria , confirm positive blood smear asexual form P. falciparum ( mixed nonfalciparum specie ) Asexual P. falciparum parasitaemia : 10,000 200,000/uL , determine thin thick blood film Fever define &gt; 37.5Â°C tympanic temperature history fever within last 24 hour Written inform consent ( legally acceptable representative case child ) Willingness ability patients/guardians comply study protocol duration study Signs severe/complicated malaria ( WHO , 2000 ) Haematocrit &lt; 25 % haemoglobin ( Hb ) &lt; 8 g/dL enrollment Acute illness malaria require treatment For female : pregnancy , breast feeding Patients receive artemisinin derivative artemisinincontaining combination therapy ( ACT ) within previous 7 day History allergy know contraindication artemisinins , ACT use site Previous splenectomy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Uncomplicated P. falciparum malaria</keyword>
</DOC>